経口FXIa阻害剤BAY 2433334の適切な投与量に関する情報を収集し、心臓関連の合併症を引き起こす可能性のある不整脈（心房細動）患者における、非ビタミンK経口抗凝固薬（NOAC）であるアピキサバンとの安全性を比較する研究。

基本情報

NCT ID

NCT04218266

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

755

治験依頼者名

Bayer

概要

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral anticoagulant (NOAC) in patients with atrial fibrillation. This study is also done to learn how the drug in this study moves into, through and out of the body. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor. Apixaban, works by reducing the production of blood clotting factors in our body and thins the blood and is a so called non-vitamin K oral anticoagulant (NOAC). Thinning the blood can prevent you from blood clots which can cause a stroke.

対象疾患

介入

依頼者（Sponsor）

実施施設 (9)